{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T15:47:46Z","timestamp":1770220066720,"version":"3.49.0"},"reference-count":126,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T00:00:00Z","timestamp":1770163200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T00:00:00Z","timestamp":1770163200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Cardiol Rep"],"DOI":"10.1007\/s11886-025-02340-6","type":"journal-article","created":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T04:22:16Z","timestamp":1770178936000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cardiorenal and Metabolic Dimensions of Cardiomyopathies and Heart Failure: Focus on SGLT2i, GLP1-RA, and ns-MRA"],"prefix":"10.1007","volume":"28","author":[{"given":"Carla","family":"Indennidate","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brigitta","family":"Perencin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vittorio","family":"Di Maso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iris","family":"Buda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Riccardo","family":"Candido","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gianfranco","family":"Sinagra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Merlo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,4]]},"reference":[{"key":"2340_CR1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehm342","author":"P Elliott","year":"2008","unstructured":"Elliott P, et al. Classification of the cardiomyopathies: a position statement from the European society of cardiology working group on myocardial and pericardial diseases. Eur Heart J. 2008. https:\/\/doi.org\/10.1093\/eurheartj\/ehm342.","journal-title":"Eur Heart J"},{"key":"2340_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-43343-z","author":"J Mei","year":"2023","unstructured":"Mei J, et al. Impacts of obesity on global subclinical left cardiac function represented by CMR-derived myocardial strain, TyG index may be a predictor. Sci Rep. 2023. https:\/\/doi.org\/10.1038\/s41598-023-43343-z.","journal-title":"Sci Rep"},{"key":"2340_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcrp.2024.200338","author":"V Rizza","year":"2024","unstructured":"Rizza V, et al. Diabetic cardiomyopathy: pathophysiology, imaging assessment and therapeutical strategies. International Journal of Cardiology Cardiovascular Risk and Prevention. 2024. https:\/\/doi.org\/10.1016\/j.ijcrp.2024.200338.","journal-title":"International Journal of Cardiology Cardiovascular Risk and Prevention"},{"issue":"5","key":"2340_CR4","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1038\/s41581-025-00957-y","volume":"21","author":"EF Carney","year":"2025","unstructured":"Carney EF. Cardiovascular mortality increases with stage of cardiovascular\u2013kidney\u2013metabolic syndrome. Nat Rev Nephrol. 2025;21(5):283\u2013283. https:\/\/doi.org\/10.1038\/s41581-025-00957-y.","journal-title":"Nat Rev Nephrol"},{"key":"2340_CR5","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.0000000637","author":"SE Claudel","year":"2025","unstructured":"Claudel SE, Schmidt IM, Waikar SS, Verma A. Cumulative incidence of mortality associated with cardiovascular\u2013kidney\u2013metabolic (CKM) syndrome. J Am Soc Nephrol. 2025. https:\/\/doi.org\/10.1681\/ASN.0000000637.","journal-title":"J Am Soc Nephrol"},{"key":"2340_CR6","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.120.050686","author":"J Jankowski","year":"2021","unstructured":"Jankowski J, Floege J, Fliser D, B\u00f6hm M, Marx N. Cardiovascular disease in chronic kidney disease pathophysiological insights and therapeutic options. Circulation. 2021. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.120.050686.","journal-title":"Circulation"},{"key":"2340_CR7","doi-asserted-by":"publisher","unstructured":"Rangaswami J, et al. Cardiorenal syndrome: Classification, Pathophysiology, Diagnosis, and treatment strategies: A scientific statement from the American heart association. Circulation. 2019;139(16). https:\/\/doi.org\/10.1161\/CIR.0000000000000664.","DOI":"10.1161\/CIR.0000000000000664"},{"key":"2340_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.pcad.2019.07.003","author":"E Braunwald","year":"2019","unstructured":"Braunwald E. Diabetes, heart failure, and renal dysfunction: the vicious circles. Prog Cardiovasc Dis. 2019. https:\/\/doi.org\/10.1016\/j.pcad.2019.07.003.","journal-title":"Prog Cardiovasc Dis"},{"issue":"7","key":"2340_CR9","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1002\/ejhf.1914","volume":"22","author":"M Merlo","year":"2020","unstructured":"Merlo M, et al. Contemporary survival trends and aetiological characterization in non-ischaemic dilated cardiomyopathy. Eur J Heart Fail. 2020;22(7):1111\u201321. https:\/\/doi.org\/10.1002\/ejhf.1914.","journal-title":"Eur J Heart Fail"},{"key":"2340_CR10","doi-asserted-by":"publisher","unstructured":"Canepa M, et al. Temporal trend of age at diagnosis in hypertrophic cardiomyopathy. Circ Heart Fail. 2020;13(9). https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.120.007230.","DOI":"10.1161\/CIRCHEARTFAILURE.120.007230"},{"key":"2340_CR11","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000001184","author":"CE Ndumele","year":"2023","unstructured":"Ndumele CE, et al. Cardiovascular-Kidney-Metabolic health: a presidential advisory from the American Heart Association. Circulation. 2023. https:\/\/doi.org\/10.1161\/CIR.0000000000001184.","journal-title":"Circulation"},{"issue":"1","key":"2340_CR12","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.jacbts.2022.05.010","volume":"8","author":"B Bozkurt","year":"2023","unstructured":"Bozkurt B, Nair AP, Misra A, Scott CZ, Mahar JH, Fedson S. Neprilysin inhibitors in heart failure. JACC: Basic to Translational Science. 2023;8(1):88\u2013105. https:\/\/doi.org\/10.1016\/j.jacbts.2022.05.010.","journal-title":"JACC: Basic to Translational Science"},{"issue":"37","key":"2340_CR13","doi-asserted-by":"publisher","first-page":"3503","DOI":"10.1093\/eurheartj\/ehad194","volume":"44","author":"E Arbelo","year":"2023","unstructured":"Arbelo E, et al. ESC Guidelines for the management of cardiomyopathies. Eur Heart J. 2023;44(37):3503\u2013626. https:\/\/doi.org\/10.1093\/eurheartj\/ehad194.","journal-title":"Eur Heart J."},{"key":"2340_CR14","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.121.318241","author":"GD Lopaschuk","year":"2021","unstructured":"Lopaschuk GD, Karwi QG, Tian R, Wende AR, Abel ED. Cardiac energy metabolism in heart failure. Circ Res. 2021. https:\/\/doi.org\/10.1161\/CIRCRESAHA.121.318241.","journal-title":"Circ Res"},{"key":"2340_CR15","doi-asserted-by":"publisher","DOI":"10.1056\/nejmra063052","author":"S Neubauer","year":"2007","unstructured":"Neubauer S. The failing heart \u2014 an engine out of fuel. N Engl J Med. 2007. https:\/\/doi.org\/10.1056\/nejmra063052.","journal-title":"N Engl J Med"},{"issue":"1","key":"2340_CR16","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1152\/physrev.00015.2009","volume":"90","author":"GD Lopaschuk","year":"2010","unstructured":"Lopaschuk GD, Ussher JR, Folmes CDL, Jaswal JS, Stanley WC. Myocardial fatty acid metabolism in health and disease. Physiol Rev. 2010;90(1):207\u201358. https:\/\/doi.org\/10.1152\/physrev.00015.2009.","journal-title":"Physiol Rev"},{"key":"2340_CR17","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.106.679597","author":"S Boudina","year":"2007","unstructured":"Boudina S, Abel ED. Diabetic cardiomyopathy revisited. Circulation. 2007. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.106.679597.","journal-title":"Circulation"},{"key":"2340_CR18","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvq239","author":"H Bugger","year":"2010","unstructured":"Bugger H, Abel ED. Mitochondria in the diabetic heart. Cardiovasc Res. 2010. https:\/\/doi.org\/10.1093\/cvr\/cvq239.","journal-title":"Cardiovasc Res"},{"key":"2340_CR19","doi-asserted-by":"publisher","DOI":"10.1007\/s11897-017-0337-9","author":"S Van Linthout","year":"2017","unstructured":"Van Linthout S, Tsch\u00f6pe C. Inflammation \u2013 cause or consequence of heart failure or both? Curr Heart Fail Rep. 2017. https:\/\/doi.org\/10.1007\/s11897-017-0337-9.","journal-title":"Curr Heart Fail Rep"},{"key":"2340_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.tem.2011.07.003","author":"G Iacobellis","year":"2011","unstructured":"Iacobellis G, Bianco AC. Epicardial adipose tissue: emerging physiological, pathophysiological and clinical features. Trends Endocrinol Metab. 2011. https:\/\/doi.org\/10.1016\/j.tem.2011.07.003.","journal-title":"Trends Endocrinol Metab"},{"key":"2340_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2025.06.055","author":"M Packer","year":"2025","unstructured":"Packer M. The adipokine hypothesis of heart failure with a preserved ejection fraction. JACC. 2025. https:\/\/doi.org\/10.1016\/j.jacc.2025.06.055.","journal-title":"JACC"},{"issue":"18","key":"2340_CR22","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1016\/j.jacc.2025.03.009","volume":"85","author":"M Packer","year":"2025","unstructured":"Packer M, Zile MR, Kramer CM, Murakami M, Ou Y, Borlaug BA. Interplay of chronic kidney disease and the effects of Tirzepatide in patients with heart failure, preserved ejection fraction, and obesity. J Am Coll Cardiol. 2025;85(18):1721\u201335. https:\/\/doi.org\/10.1016\/j.jacc.2025.03.009.","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"2340_CR23","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.1093\/ckj\/sfad085","volume":"16","author":"CVC Junho","year":"2023","unstructured":"Junho CVC, Frisch J, Soppert J, Wollenhaupt J, Noels H. Cardiomyopathy in chronic kidney disease: clinical features, biomarkers and the contribution of murine models in understanding pathophysiology. Clin Kidney J. 2023;16(11):1786\u2013803. https:\/\/doi.org\/10.1093\/ckj\/sfad085.","journal-title":"Clin Kidney J"},{"issue":"2","key":"2340_CR24","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/nrneph.2012.279","volume":"9","author":"P Hatamizadeh","year":"2013","unstructured":"Hatamizadeh P, Fonarow GC, Budoff MJ, Darabian S, Kovesdy CP, Kalantar-Zadeh K. Cardiorenal syndrome: pathophysiology and potential targets for clinical management. Nat Rev Nephrol. 2013;9(2):99\u2013111. https:\/\/doi.org\/10.1038\/nrneph.2012.279.","journal-title":"Nat Rev Nephrol"},{"issue":"11","key":"2340_CR25","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1161\/CIRCRESAHA.124.325488","volume":"136","author":"H Noels","year":"2025","unstructured":"Noels H, et al. Renal-cardiac crosstalk in the pathogenesis and progression of heart failure. Circ Res. 2025;136(11):1306\u201334. https:\/\/doi.org\/10.1161\/CIRCRESAHA.124.325488.","journal-title":"Circ Res"},{"key":"2340_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2012\/319432","volume":"2012","author":"J Park","year":"2012","unstructured":"Park J. Cardiovascular risk in chronic kidney disease: role of the sympathetic nervous system. Cardiol Res Pract. 2012;2012:1\u20138. https:\/\/doi.org\/10.1155\/2012\/319432.","journal-title":"Cardiol Res Pract"},{"key":"2340_CR27","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2018.12.044","author":"E Ku","year":"2019","unstructured":"Ku E, Lee BJ, Wei J, Weir MR. Hypertension in CKD: core curriculum 2019. Am J Kidney Dis. 2019. https:\/\/doi.org\/10.1053\/j.ajkd.2018.12.044.","journal-title":"Am J Kidney Dis"},{"key":"2340_CR28","unstructured":"A. Stupin, I. Drenjancevic, L. Rasic, A. Cosic, and M. Stupin, A Cross-Talk between the Renin-Angiotensin and Adrenergic System. Southeastern, 2017."},{"issue":"6","key":"2340_CR29","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1159\/000313363","volume":"31","author":"HM Siragy","year":"2010","unstructured":"Siragy HM, Carey RM. Role of the intrarenal renin-angiotensin-aldosterone system in chronic kidney disease. Am J Nephrol. 2010;31(6):541\u201350. https:\/\/doi.org\/10.1159\/000313363.","journal-title":"Am J Nephrol"},{"issue":"6","key":"2340_CR30","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1172\/JCI112528","volume":"77","author":"S Anderson","year":"1986","unstructured":"Anderson S, Rennke HG, Brenner BM. Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat. J Clin Invest. 1986;77(6):1993\u20132000. https:\/\/doi.org\/10.1172\/JCI112528.","journal-title":"J Clin Invest"},{"issue":"2","key":"2340_CR31","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.cardfail.2006.11.005","volume":"13","author":"Y Li","year":"2007","unstructured":"Li Y, et al. Molecular signaling mediated by Angiotensin II type 1A receptor blockade leading to attenuation of renal dysfunction-associated heart failure. J Card Fail. 2007;13(2):155\u201362. https:\/\/doi.org\/10.1016\/j.cardfail.2006.11.005.","journal-title":"J Card Fail"},{"issue":"3","key":"2340_CR32","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1093\/ajh\/hpac124","volume":"36","author":"PI Georgianos","year":"2023","unstructured":"Georgianos PI, Agarwal R. The nonsteroidal mineralocorticoid-receptor-antagonist finerenone in cardiorenal medicine: a state-of-the-art review of the literature. Am J Hypertens. 2023;36(3):135\u201343. https:\/\/doi.org\/10.1093\/ajh\/hpac124.","journal-title":"Am J Hypertens"},{"issue":"6","key":"2340_CR33","doi-asserted-by":"publisher","first-page":"F654","DOI":"10.1152\/ajprenal.00396.2021","volume":"323","author":"H Tanaka","year":"2022","unstructured":"Tanaka H, et al. Interleukin-6 Blockade reduces salt-induced cardiac inflammation and fibrosis in subtotal nephrectomized mice. Am J Physiology-Renal Physiol. 2022;323(6):F654-65. https:\/\/doi.org\/10.1152\/ajprenal.00396.2021.","journal-title":"Am J Physiology-Renal Physiol."},{"issue":"11","key":"2340_CR34","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0142456","volume":"10","author":"Y Zhang","year":"2015","unstructured":"Zhang Y, et al. TAK-242, a toll-like receptor 4 antagonist, protects against Aldosterone-Induced cardiac and renal injury. PLoS One. 2015;10(11):e0142456. https:\/\/doi.org\/10.1371\/journal.pone.0142456.","journal-title":"PLoS One"},{"issue":"22","key":"2340_CR35","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21228868","volume":"21","author":"M Gil-Fern\u00e1ndez","year":"2020","unstructured":"Gil-Fern\u00e1ndez M, et al. Genetic deletion of NOD1 prevents cardiac Ca2\u2009+\u2009mishandling induced by experimental chronic kidney disease. Int J Mol Sci. 2020;21(22):8868. https:\/\/doi.org\/10.3390\/ijms21228868.","journal-title":"Int J Mol Sci"},{"key":"2340_CR36","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2021.686249","author":"CA Falconi","year":"2021","unstructured":"Falconi CA, et al. , \u201cUremic toxins: an alarming danger concerning the cardiovascular system,.\u201d Front Physiol. 2021. https:\/\/doi.org\/10.3389\/fphys.2021.686249.","journal-title":"Front Physiol"},{"issue":"1","key":"2340_CR37","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23010531","volume":"23","author":"E Harlacher","year":"2022","unstructured":"Harlacher E, Wollenhaupt J, Baaten CCFMJ, Noels H. Impact of uremic toxins on endothelial dysfunction in chronic kidney disease: a systematic review. Int J Mol Sci. 2022;23(1):531. https:\/\/doi.org\/10.3390\/ijms23010531.","journal-title":"Int J Mol Sci"},{"key":"2340_CR38","doi-asserted-by":"publisher","unstructured":"Han H, et al. Cresyl sulfate aggravates cardiac dysfunction associated with chronic kidney disease by enhancing apoptosis of cardiomyocytes. J Am Heart Assoc. 2015;4(6). https:\/\/doi.org\/10.1161\/JAHA.115.001852.","DOI":"10.1161\/JAHA.115.001852"},{"issue":"11","key":"2340_CR39","doi-asserted-by":"publisher","first-page":"4393","DOI":"10.1172\/JCI46122","volume":"121","author":"C Faul","year":"2011","unstructured":"Faul C, et al. FGF23 induces left ventricular hypertrophy. J Clin Invest. 2011;121(11):4393\u2013408. https:\/\/doi.org\/10.1172\/JCI46122.","journal-title":"J Clin Invest"},{"issue":"6","key":"2340_CR40","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1016\/j.cmet.2015.09.002","volume":"22","author":"A Grabner","year":"2015","unstructured":"Grabner A, et al. Activation of cardiac fibroblast growth factor receptor 4 causes left ventricular hypertrophy. Cell Metab. 2015;22(6):1020\u201332. https:\/\/doi.org\/10.1016\/j.cmet.2015.09.002.","journal-title":"Cell Metab"},{"issue":"4","key":"2340_CR41","doi-asserted-by":"publisher","first-page":"913","DOI":"10.2215\/CJN.06040710","volume":"6","author":"J Cunningham","year":"2011","unstructured":"Cunningham J, Locatelli F, Rodriguez M. Secondary hyperparathyroidism. Clin J Am Soc Nephrol. 2011;6(4):913\u201321. https:\/\/doi.org\/10.2215\/CJN.06040710.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"5","key":"2340_CR42","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1681\/ASN.2014040325","volume":"26","author":"J Xie","year":"2015","unstructured":"Xie J, Yoon J, An S-W, Kuro-o M, Huang C-L. Soluble Klotho protects against uremic cardiomyopathy independently of fibroblast growth factor 23 and phosphate. J Am Soc Nephrol. 2015;26(5):1150\u201360. https:\/\/doi.org\/10.1681\/ASN.2014040325.","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"2340_CR43","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.cardiores.2004.02.003","volume":"63","author":"C Proud","year":"2004","unstructured":"Proud C. Ras, PI3-kinase and mTOR signaling in cardiac hypertrophy. Cardiovasc Res. 2004;63(3):403\u201313. https:\/\/doi.org\/10.1016\/j.cardiores.2004.02.003.","journal-title":"Cardiovasc Res"},{"key":"2340_CR44","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.00055.2009","author":"EM Wright","year":"2011","unstructured":"Wright EM, Loo DDFL, Hirayama BA. Biology of human sodium glucose transporters. Physiol Rev. 2011. https:\/\/doi.org\/10.1152\/physrev.00055.2009.","journal-title":"Physiol Rev"},{"issue":"22","key":"2340_CR45","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117\u201328. https:\/\/doi.org\/10.1056\/NEJMoa1504720.","journal-title":"N Engl J Med"},{"key":"2340_CR46","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12829","author":"B Neal","year":"2017","unstructured":"Neal B, et al. Rationale, design and baseline characteristics of the CANagliflozin cardioVascular assessment study\u2013renal (CANVAS-R): a randomized, placebo-controlled trial. Diabetes Obes Metab. 2017. https:\/\/doi.org\/10.1111\/dom.12829.","journal-title":"Diabetes Obes Metab"},{"key":"2340_CR47","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1812389","author":"SD Wiviott","year":"2019","unstructured":"Wiviott SD, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019. https:\/\/doi.org\/10.1056\/nejmoa1812389.","journal-title":"N Engl J Med"},{"key":"2340_CR48","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2004967","author":"CP Cannon","year":"2020","unstructured":"Cannon CP. Cardiovascular outcomes with ertugliflozin in type 2 diabetes. N Engl J Med. 2020. https:\/\/doi.org\/10.1056\/nejmoa2004967.","journal-title":"N Engl J Med"},{"key":"2340_CR49","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1911303","author":"JJV McMurray","year":"2019","unstructured":"McMurray JJV, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019. https:\/\/doi.org\/10.1056\/NEJMoa1911303.","journal-title":"N Engl J Med"},{"key":"2340_CR50","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2022190","author":"M Packer","year":"2020","unstructured":"Packer M, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020. https:\/\/doi.org\/10.1056\/NEJMoa2022190.","journal-title":"N Engl J Med"},{"issue":"16","key":"2340_CR51","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/nejmoa2107038","volume":"385","author":"SD Anker","year":"2021","unstructured":"Anker SD, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021;385(16):1451\u201361. https:\/\/doi.org\/10.1056\/nejmoa2107038.","journal-title":"N Engl J Med"},{"key":"2340_CR52","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2206286","author":"SD Solomon","year":"2022","unstructured":"Solomon SD. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med. 2022. https:\/\/doi.org\/10.1056\/nejmoa2206286.","journal-title":"N Engl J Med"},{"key":"2340_CR53","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1611925","author":"B Neal","year":"2017","unstructured":"Neal B, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017. https:\/\/doi.org\/10.1056\/nejmoa1611925.","journal-title":"N Engl J Med"},{"key":"2340_CR54","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2024816","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink HJL, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020. https:\/\/doi.org\/10.1056\/nejmoa2024816.","journal-title":"N Engl J Med"},{"key":"2340_CR55","doi-asserted-by":"publisher","DOI":"10.7326\/M22-2904","author":"SD Navaneethan","year":"2023","unstructured":"Navaneethan SD, et al. Diabetes management in chronic kidney disease: synopsis of the KDIGO 2022 clinical practice guideline update. Ann Intern Med. 2023. https:\/\/doi.org\/10.7326\/M22-2904.","journal-title":"Ann Intern Med"},{"key":"2340_CR56","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab368","author":"TA McDonagh","year":"2021","unstructured":"McDonagh TA, et al. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021. https:\/\/doi.org\/10.1093\/eurheartj\/ehab368.","journal-title":"Eur Heart J"},{"key":"2340_CR57","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1607141","author":"SP Marso","year":"2016","unstructured":"Marso SP, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016. https:\/\/doi.org\/10.1056\/nejmoa1607141.","journal-title":"N Engl J Med"},{"issue":"4","key":"2340_CR58","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1603827","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311\u201322. https:\/\/doi.org\/10.1056\/NEJMoa1603827.","journal-title":"N Engl J Med"},{"key":"2340_CR59","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31149-3","author":"HC Gerstein","year":"2019","unstructured":"Gerstein HC, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019. https:\/\/doi.org\/10.1016\/S0140-6736(19)31149-3.","journal-title":"Lancet"},{"key":"2340_CR60","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1901118","author":"M Husain","year":"2019","unstructured":"Husain M, et al. Oral Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2019. https:\/\/doi.org\/10.1056\/nejmoa1901118.","journal-title":"N Engl J Med"},{"key":"2340_CR61","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2307563","author":"AM Lincoff","year":"2023","unstructured":"Lincoff AM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023. https:\/\/doi.org\/10.1056\/nejmoa2307563.","journal-title":"N Engl J Med"},{"key":"2340_CR62","doi-asserted-by":"publisher","DOI":"10.1016\/j.cardfail.2023.10.465","author":"J Butler","year":"2024","unstructured":"Butler J, et al. Effects of semaglutide across the range of left ventricular ejection fraction in obesity phenotype of heart failure with preserved ejection fraction: the STEP-HFpEF trial. J Card Fail. 2024. https:\/\/doi.org\/10.1016\/j.cardfail.2023.10.465.","journal-title":"J Card Fail"},{"issue":"10","key":"2340_CR63","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/S2213-8587(21)00203-5","volume":"9","author":"N Sattar","year":"2021","unstructured":"Sattar N, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. Lancet Diabetes Endocrinol. 2021;9(10):653\u201362. https:\/\/doi.org\/10.1016\/S2213-8587(21)00203-5.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"2340_CR64","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1056\/NEJMoa2403347","volume":"391","author":"V Perkovic","year":"2024","unstructured":"Perkovic V, et al. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. N Engl J Med. 2024;391(2):109\u201321. https:\/\/doi.org\/10.1056\/NEJMoa2403347.","journal-title":"N Engl J Med"},{"key":"2340_CR65","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2107519","author":"JP Fr\u00edas","year":"2021","unstructured":"Fr\u00edas JP, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med. 2021. https:\/\/doi.org\/10.1056\/nejmoa2107519.","journal-title":"N Engl J Med"},{"issue":"5","key":"2340_CR66","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1056\/NEJMoa2410027","volume":"392","author":"M Packer","year":"2025","unstructured":"Packer M, et al. Tirzepatide for heart failure with preserved ejection fraction and obesity. N Engl J Med. 2025;392(5):427\u201337. https:\/\/doi.org\/10.1056\/NEJMoa2410027.","journal-title":"N Engl J Med"},{"issue":"23","key":"2340_CR67","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","volume":"383","author":"GL Bakris","year":"2020","unstructured":"Bakris GL, et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med. 2020;383(23):2219\u201329. https:\/\/doi.org\/10.1056\/NEJMoa2025845.","journal-title":"N Engl J Med"},{"issue":"24","key":"2340_CR68","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","volume":"385","author":"B Pitt","year":"2021","unstructured":"Pitt B, et al. Cardiovascular events with finerenone in kidney disease and type 2 diabetes. N Engl J Med. 2021;385(24):2252\u201363. https:\/\/doi.org\/10.1056\/NEJMoa2110956.","journal-title":"N Engl J Med"},{"key":"2340_CR69","doi-asserted-by":"publisher","unstructured":"Yu W, et al. Adverse effects of finerenone in patients with heart failure: a systematic review and meta-analysis. Front Cardiovasc Med. 2025;12. https:\/\/doi.org\/10.3389\/fcvm.2025.1601552.","DOI":"10.3389\/fcvm.2025.1601552"},{"issue":"6","key":"2340_CR70","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","volume":"43","author":"R Agarwal","year":"2022","unstructured":"Agarwal R, et al. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. Eur Heart J. 2022;43(6):474\u201384. https:\/\/doi.org\/10.1093\/eurheartj\/ehab777.","journal-title":"Eur Heart J."},{"issue":"2","key":"2340_CR71","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.jacc.2024.10.091","volume":"85","author":"FR Mc Causland","year":"2025","unstructured":"Mc Causland FR, et al. Finerenone and kidney outcomes in patients with heart failure. J Am Coll Cardiol. 2025;85(2):159\u201368. https:\/\/doi.org\/10.1016\/j.jacc.2024.10.091.","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"2340_CR72","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1038\/s41440-025-02175-2","volume":"48","author":"A Sato","year":"2025","unstructured":"Sato A, Nishimoto M. Real-world use of finerenone in patients with chronic kidney disease and type 2 diabetes based on large-scale clinical studies: FIDELIO-DKD and FIGARO-DKD. Hypertens Res. 2025;48(6):1929\u201338. https:\/\/doi.org\/10.1038\/s41440-025-02175-2.","journal-title":"Hypertens Res"},{"issue":"6","key":"2340_CR73","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1056\/NEJMoa2410659","volume":"393","author":"R Agarwal","year":"2025","unstructured":"Agarwal R, et al. Finerenone with empagliflozin in chronic kidney disease and type 2 diabetes. N Engl J Med. 2025;393(6):533\u201343. https:\/\/doi.org\/10.1056\/NEJMoa2410659.","journal-title":"N Engl J Med"},{"issue":"17","key":"2340_CR74","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1016\/j.jacc.2025.03.429","volume":"85","author":"MA Pabon","year":"2025","unstructured":"Pabon MA, et al. Finerenone reduces New-Onset atrial fibrillation across the spectrum of Cardio-Kidney-Metabolic syndrome. J Am Coll Cardiol. 2025;85(17):1649\u201360. https:\/\/doi.org\/10.1016\/j.jacc.2025.03.429.","journal-title":"J Am Coll Cardiol."},{"key":"2340_CR75","doi-asserted-by":"publisher","DOI":"10.1038\/s41569-024-01074-2","author":"M Gigli","year":"2024","unstructured":"Gigli M, Stolfo D, Merlo M, Sinagra G, Taylor MRG, Mestroni L. Pathophysiology of dilated cardiomyopathy: from mechanisms to precision medicine. Nature Research. 2024. https:\/\/doi.org\/10.1038\/s41569-024-01074-2.","journal-title":"Nature Research"},{"key":"2340_CR76","doi-asserted-by":"publisher","DOI":"10.1007\/s11886-025-02241-8","volume-title":"The Impact of Cardio-Renal-Metabolic Profile in Dilated Cardiomyopathy","author":"T Akbari","year":"2025","unstructured":"Akbari T, Hammersley DJ, May CYY, Halliday BP, Prasad SK. The Impact of Cardio-Renal-Metabolic Profile in Dilated Cardiomyopathy. Springer; 2025. https:\/\/doi.org\/10.1007\/s11886-025-02241-8."},{"issue":"5","key":"2340_CR77","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1159\/000531534","volume":"148","author":"E Dziewi\u0119cka","year":"2023","unstructured":"Dziewi\u0119cka E, et al. Comparison of clinical course and outcomes between dilated and hypokinetic non-dilated cardiomyopathy. Cardiology. 2023;148(5):395\u2013401. https:\/\/doi.org\/10.1159\/000531534.","journal-title":"Cardiology"},{"key":"2340_CR78","doi-asserted-by":"publisher","DOI":"10.1002\/ehf2.14711","author":"Y Eda","year":"2024","unstructured":"Eda Y, et al. Non-dilated left ventricular cardiomyopathy vs. dilated cardiomyopathy: clinical background and outcomes. ESC Heart Fail. 2024. https:\/\/doi.org\/10.1002\/ehf2.14711.","journal-title":"ESC Heart Fail"},{"key":"2340_CR79","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0234260","author":"C Meindl","year":"2020","unstructured":"Meindl C, et al. The role of diabetes in cardiomyopathies of different etiologies-characteristics and 1-year follow-up results of the EVITA-HF registry. PLoS One. 2020. https:\/\/doi.org\/10.1371\/journal.pone.0234260.","journal-title":"PLoS One"},{"key":"2340_CR80","doi-asserted-by":"publisher","DOI":"10.1002\/ehf2.13816","author":"J Silverdal","year":"2022","unstructured":"Silverdal J, Sj\u00f6land H, Pivodic A, Dahlstr\u00f6m U, Fu M, Bollano E. Prognostic differences in long-standing vs. recent-onset dilated cardiomyopathy. ESC Heart Fail. 2022. https:\/\/doi.org\/10.1002\/ehf2.13816.","journal-title":"ESC Heart Fail"},{"issue":"4","key":"2340_CR81","doi-asserted-by":"publisher","first-page":"2334","DOI":"10.1002\/ehf2.14810","volume":"11","author":"J \u00d6sterman","year":"2024","unstructured":"\u00d6sterman J, Al-Sodany E, Haugen L\u00f6fman I, Barany P, Evans M. Heart failure: the grim reaper of the cardio\u2010renal\u2010metabolic triad. ESC Heart Fail. 2024;11(4):2334\u201343. https:\/\/doi.org\/10.1002\/ehf2.14810.","journal-title":"ESC Heart Fail"},{"key":"2340_CR82","doi-asserted-by":"publisher","unstructured":"Huang L, et al. Obesity paradox in heart failure revisited: etiology as effect modifier. Am J Cardiol. 2023;207:294\u2013301. https:\/\/doi.org\/10.1016\/j.amjcard.2023.09.024.","DOI":"10.1016\/j.amjcard.2023.09.024"},{"key":"2340_CR83","doi-asserted-by":"publisher","unstructured":"Tanaka H, Tatsumi K, Matsuzoe H, Matsumoto K, Hirata KI. Impact of diabetes mellitus on left ventricular longitudinal function of patients with non-ischemic dilated cardiomyopathy. Cardiovasc Diabetol. 2020;19(1). https:\/\/doi.org\/10.1186\/s12933-020-01063-y.","DOI":"10.1186\/s12933-020-01063-y"},{"key":"2340_CR84","doi-asserted-by":"publisher","unstructured":"Sakakibara M, et al. Association of diabetes mellitus with myocardial collagen accumulation and relaxation impairment in patients with dilated cardiomyopathy. Diabetes Res Clin Pract. 2011;92(3). https:\/\/doi.org\/10.1016\/j.diabres.2011.02.023.","DOI":"10.1016\/j.diabres.2011.02.023"},{"key":"2340_CR85","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehn153","author":"MR MacDonald","year":"2008","unstructured":"MacDonald MR, et al. Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure - an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. Eur Heart J. 2008. https:\/\/doi.org\/10.1093\/eurheartj\/ehn153.","journal-title":"Eur Heart J"},{"key":"2340_CR86","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.121.052792","author":"IE Beldhuis","year":"2022","unstructured":"Beldhuis IE, et al. Evidence-based medical therapy in patients with heart failure with reduced ejection fraction and chronic kidney disease. Circulation. 2022. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.121.052792.","journal-title":"Circulation"},{"key":"2340_CR87","doi-asserted-by":"publisher","unstructured":"Guaricci AI et al. Assessment and management of heart failure in patients with chronic kidney disease. 2024. https:\/\/doi.org\/10.1007\/s10741-023-10346-x","DOI":"10.1007\/s10741-023-10346-x"},{"key":"2340_CR88","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcha.2018.02.005","author":"M Merlo","year":"2018","unstructured":"Merlo M, Caiffa T, Gobbo M, Adamo L, Sinagra G. Reverse remodeling in dilated cardiomyopathy: insights and future perspectives. IJC Heart Vasc. 2018. https:\/\/doi.org\/10.1016\/j.ijcha.2018.02.005.","journal-title":"IJC Heart Vasc"},{"key":"2340_CR89","doi-asserted-by":"publisher","unstructured":"Xu Y, et al. Myocardial Tissue Reverse Remodeling After Guideline-Directed Medical Therapy in Idiopathic Dilated Cardiomyopathy. Circ Heart Fail. 2021;14(1). https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.120.007944.","DOI":"10.1161\/CIRCHEARTFAILURE.120.007944"},{"key":"2340_CR90","doi-asserted-by":"publisher","unstructured":"Neves JS, Packer M, Ferreira JP. Increased risk of heart failure hospitalization with GLP-1 receptor agonists in patients with reduced ejection fraction: a meta-analysis of the EXSCEL and FIGHT trials. J Card Fail. 2023;29(7):1107\u20139. https:\/\/doi.org\/10.1016\/j.cardfail.2023.03.017.","DOI":"10.1016\/j.cardfail.2023.03.017"},{"issue":"5","key":"2340_CR91","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1016\/j.jchf.2024.12.004","volume":"13","author":"P Karlstr\u00f6m","year":"2025","unstructured":"Karlstr\u00f6m P, Pivodic A, Fu M. Glucagon-like peptide 1 receptor agonist is associated with improved survival in overweight heart failure patients. JACC: Heart Failure. 2025;13(5):754\u201366. https:\/\/doi.org\/10.1016\/j.jchf.2024.12.004.","journal-title":"JACC: Heart Failure"},{"issue":"3","key":"2340_CR92","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1002\/ehf2.14711","volume":"11","author":"Y Eda","year":"2024","unstructured":"Eda Y, et al. Non-dilated left ventricular cardiomyopathy vs. dilated cardiomyopathy: clinical background and outcomes. ESC Heart Fail. 2024;11(3):1463\u201371. https:\/\/doi.org\/10.1002\/ehf2.14711.","journal-title":"ESC Heart Fail"},{"issue":"4","key":"2340_CR93","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/j.jacep.2021.12.002","volume":"8","author":"AD Krahn","year":"2022","unstructured":"Krahn AD, et al. Arrhythmogenic Right Ventricular Cardiomyopathy. JACC: Clinical Electrophysiology. 2022;8(4):533\u201353. https:\/\/doi.org\/10.1016\/j.jacep.2021.12.002.","journal-title":"JACC: Clinical Electrophysiology"},{"key":"2340_CR94","doi-asserted-by":"publisher","unstructured":"Yang Z, et al. SGLT2 inhibitor Dapagliflozin attenuates cardiac fibrosis and inflammation by reverting the HIF-2\u03b1 signaling pathway in arrhythmogenic cardiomyopathy. FASEB J Jul. 2022;36(7). https:\/\/doi.org\/10.1096\/fj.202200243R.","DOI":"10.1096\/fj.202200243R"},{"issue":"40","key":"2340_CR95","doi-asserted-by":"publisher","first-page":"3297","DOI":"10.1093\/eurheartj\/ehz641","volume":"40","author":"B Pieske","year":"2019","unstructured":"Pieske B, et al. How to diagnose heart failure with preserved ejection fraction: the HFA\u2013PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). Eur Heart J. 2019;40(40):3297\u2013317. https:\/\/doi.org\/10.1093\/eurheartj\/ehz641.","journal-title":"Eur Heart J"},{"issue":"5","key":"2340_CR96","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1002\/ejhf.1461","volume":"21","author":"PM Seferovi\u0107","year":"2019","unstructured":"Seferovi\u0107 PM, et al. Heart failure in cardiomyopathies: a position paper from the heart failure association of the European society of cardiology. Eur J Heart Fail. 2019;21(5):553\u201376. https:\/\/doi.org\/10.1002\/ejhf.1461.","journal-title":"Eur J Heart Fail."},{"issue":"17","key":"2340_CR97","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1177\/2047487319889714","volume":"27","author":"J-B Park","year":"2020","unstructured":"Park J-B, et al. Obesity and metabolic health status are determinants for the clinical expression of hypertrophic cardiomyopathy. Eur J Prev Cardiol. 2020;27(17):1849\u201357. https:\/\/doi.org\/10.1177\/2047487319889714.","journal-title":"Eur J Prev Cardiol"},{"issue":"1","key":"2340_CR98","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1093\/ehjqcco\/qcac006","volume":"9","author":"LR Lopes","year":"2022","unstructured":"Lopes LR, et al. Association between common cardiovascular risk factors and clinical phenotype in patients with hypertrophic cardiomyopathy from the European Society of Cardiology (ESC) EurObservational Research Programme (EORP) Cardiomyopathy\/Myocarditis registry. European Heart Journal - Quality of Care and Clinical Outcomes. 2022;9(1):42\u201353. https:\/\/doi.org\/10.1093\/ehjqcco\/qcac006.","journal-title":"European Heart Journal - Quality of Care and Clinical Outcomes"},{"issue":"3","key":"2340_CR99","doi-asserted-by":"publisher","first-page":"198","DOI":"10.14740\/cr1659","volume":"15","author":"S Hajouli","year":"2024","unstructured":"Hajouli S, Belcher A, Annie F, Elashery A. Is type 2 diabetes mellitus an independent risk factor for mortality in hypertrophic cardiomyopathy? Cardiol Res. 2024;15(3):198\u2013204. https:\/\/doi.org\/10.14740\/cr1659.","journal-title":"Cardiol Res"},{"issue":"1","key":"2340_CR100","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1001\/jamacardio.2019.4268","volume":"5","author":"C Fumagalli","year":"2020","unstructured":"Fumagalli C, et al. Association of obesity with adverse long-term outcomes in hypertrophic cardiomyopathy. JAMA Cardiol. 2020;5(1):65. https:\/\/doi.org\/10.1001\/jamacardio.2019.4268.","journal-title":"JAMA Cardiol"},{"key":"2340_CR101","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.cca.2020.11.022","volume":"512","author":"F-Y Huang","year":"2021","unstructured":"Huang F-Y, Zhang J-L, Huang B-T, Peng Y, Chen S-J, Chen M. Renal function as a predictor of outcomes in patients with hypertrophic cardiomyopathy: a cohort study of a hospitalized population. Clin Chim Acta. 2021;512:92\u20139. https:\/\/doi.org\/10.1016\/j.cca.2020.11.022.","journal-title":"Clin Chim Acta"},{"issue":"4","key":"2340_CR102","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1002\/ejhf.2776","volume":"25","author":"A Porcari","year":"2023","unstructured":"Porcari A, et al. Prevalence, characteristics and outcomes of older patients with hereditary versus < scp > wild-type transthyretin amyloid cardiomyopathy. Eur J Heart Fail. 2023;25(4):515\u201324. https:\/\/doi.org\/10.1002\/ejhf.2776.","journal-title":"Eur J Heart Fail."},{"issue":"1","key":"2340_CR103","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1001\/jamacardio.2024.4578","volume":"10","author":"A Ioannou","year":"2025","unstructured":"Ioannou A, et al. Kidney outcomes in transthyretin amyloid cardiomyopathy. JAMA Cardiol. 2025;10(1):50. https:\/\/doi.org\/10.1001\/jamacardio.2024.4578.","journal-title":"JAMA Cardiol"},{"key":"2340_CR104","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgmr.2025.101229","volume":"43","author":"EP McCarron","year":"2025","unstructured":"McCarron EP, et al. Real-world clinical outcomes in adult patients with Fabry disease: a 20-year retrospective observational cohort study from a single centre. Mol Genet Metab Rep. 2025;43:101229. https:\/\/doi.org\/10.1016\/j.ymgmr.2025.101229.","journal-title":"Mol Genet Metab Rep"},{"issue":"1","key":"2340_CR105","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1161\/CIRCULATIONAHA.116.026807","volume":"136","author":"M Obokata","year":"2017","unstructured":"Obokata M, Reddy YNV, Pislaru SV, Melenovsky V, Borlaug BA. Evidence supporting the existence of a distinct obese phenotype of heart failure with preserved ejection fraction. Circulation. 2017;136(1):6\u201319. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.116.026807.","journal-title":"Circulation"},{"issue":"1","key":"2340_CR106","doi-asserted-by":"publisher","first-page":"26","DOI":"10.3390\/cardiogenetics14010002","volume":"14","author":"S Dhuny","year":"2024","unstructured":"Dhuny S, Wu H, David M, Chinnadurai R. Hypertrophic cardiomyopathy and chronic kidney disease: an updated review. Cardiogenetics. 2024;14(1):26\u201337. https:\/\/doi.org\/10.3390\/cardiogenetics14010002.","journal-title":"Cardiogenetics"},{"issue":"1","key":"2340_CR107","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-50993-5","volume":"9","author":"H Lee","year":"2019","unstructured":"Lee H, et al. Risk of end-stage renal disease in patients with hypertrophic cardiomyopathy: a nationwide population-based cohort study. Sci Rep. 2019;9(1):14565. https:\/\/doi.org\/10.1038\/s41598-019-50993-5.","journal-title":"Sci Rep"},{"key":"2340_CR108","doi-asserted-by":"publisher","unstructured":"Ho CY, et al. Genotype and lifetime burden of disease in hypertrophic cardiomyopathy. Circulation. 2018;138(14):1387\u201398. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.117.033200.","DOI":"10.1161\/CIRCULATIONAHA.117.033200"},{"issue":"3","key":"2340_CR109","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacadv.2024.100843","volume":"3","author":"A Aglan","year":"2024","unstructured":"Aglan A, et al. Impact of sodium-glucose cotransporter 2 inhibitors on mortality in hypertrophic cardiomyopathy. JACC: Advances. 2024;3(3):100843. https:\/\/doi.org\/10.1016\/j.jacadv.2024.100843.","journal-title":"JACC: Advances"},{"key":"2340_CR110","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2025.133082","volume":"426","author":"AR Fath","year":"2025","unstructured":"Fath AR, Aglan A, Maron MS, Phillips JS, Maron BJ, Rowin EJ. Cardiovascular outcomes of glucagon-like peptide-1 agonist in patients with obesity and hypertrophic cardiomyopathy. Int J Cardiol. 2025;426:133082. https:\/\/doi.org\/10.1016\/j.ijcard.2025.133082.","journal-title":"Int J Cardiol"},{"issue":"1","key":"2340_CR111","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1139\/bcb-2021-0365","volume":"100","author":"Y-Y Zhao","year":"2022","unstructured":"Zhao Y-Y, et al. Cardiovascular protective effects of GLP-1: a focus on the MAPK signaling pathway. Biochem Cell Biol. 2022;100(1):9\u201316. https:\/\/doi.org\/10.1139\/bcb-2021-0365.","journal-title":"Biochem Cell Biol"},{"issue":"1","key":"2340_CR112","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/s41392-024-01931-z","volume":"9","author":"Z Zheng","year":"2024","unstructured":"Zheng Z, et al. Glucagon-like peptide-1 receptor: mechanisms and advances in therapy. Signal Transduct Target Ther. 2024;9(1):234. https:\/\/doi.org\/10.1038\/s41392-024-01931-z.","journal-title":"Signal Transduct Target Ther."},{"issue":"8","key":"2340_CR113","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1161\/CIRCRESAHA.109.213199","volume":"106","author":"S Streicher","year":"2010","unstructured":"Streicher S, Ren H, Herschman H, Wang Y. MAPK-activated protein kinase-2 in cardiac hypertrophy and cyclooxygenase-2 regulation in heart. Circ Res. 2010;106(8):1434\u201343. https:\/\/doi.org\/10.1161\/CIRCRESAHA.109.213199.","journal-title":"Circ Res"},{"issue":"12","key":"2340_CR114","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.1002\/ejhf.2532","volume":"24","author":"A Aimo","year":"2022","unstructured":"Aimo A, et al. Redefining the epidemiology of cardiac amyloidosis. A systematic review and meta-analysis of screening studies. Eur J Heart Fail. 2022;24(12):2342\u201351. https:\/\/doi.org\/10.1002\/ejhf.2532.","journal-title":"Eur J Heart Fail"},{"issue":"24","key":"2340_CR115","doi-asserted-by":"publisher","first-page":"2411","DOI":"10.1016\/j.jacc.2024.03.429","volume":"83","author":"A Porcari","year":"2024","unstructured":"Porcari A, et al. SGLT2 Inhibitor Therapy in Patients With Transthyretin Amyloid Cardiomyopathy. J Am Coll Cardiol. 2024;83(24):2411\u201322. https:\/\/doi.org\/10.1016\/j.jacc.2024.03.429.","journal-title":"J Am Coll Cardiol."},{"key":"2340_CR116","doi-asserted-by":"publisher","unstructured":"Pozzan M, Indennidate C, Varr\u00e0 GG, Sinagra G, Merlo M, Pagura L. Amyloidosis and amyloidogenesis: one Name, many diseases. Elsevier Inc; 2024.\u00a0https:\/\/doi.org\/10.1016\/j.hfc.2024.02.001","DOI":"10.1016\/j.hfc.2024.02.001"},{"issue":"12","key":"2340_CR117","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1016\/j.cardfail.2024.06.009","volume":"30","author":"FM Lang","year":"2024","unstructured":"Lang FM, et al. Safety and efficacy of SGLT2 inhibitors for amyloid light-chain cardiomyopathy. J Card Fail. 2024;30(12):1641\u20136. https:\/\/doi.org\/10.1016\/j.cardfail.2024.06.009.","journal-title":"J Card Fail"},{"key":"2340_CR118","doi-asserted-by":"publisher","unstructured":"Jaiswal V, Hanif M, Kalra K, Mashkoor Y, Jaiswal A. Abstract 52: Glucagon-like peptide-1 receptor agonists use and outcomes in Cardiac Amyloidosis patients: A Propensity Matched Analysis. Stroke. 2025;56(Suppl_1).\u00a0https:\/\/doi.org\/10.1161\/str.56.suppl_1.52","DOI":"10.1161\/str.56.suppl_1.52"},{"key":"2340_CR119","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgmr.2025.101229","author":"EP McCarron","year":"2025","unstructured":"McCarron EP, et al. Real-world clinical outcomes in adult patients with Fabry disease: a 20-year retrospective observational cohort study from a single centre. Mol Genet Metab Rep. 2025. https:\/\/doi.org\/10.1016\/j.ymgmr.2025.101229.","journal-title":"Mol Genet Metab Rep"},{"issue":"3","key":"2340_CR120","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines13030624","volume":"13","author":"SE Thompson","year":"2025","unstructured":"Thompson SE, Roy A, Geberhiwot T, Gehmlich K, Steeds RP. Fabry disease: insights into pathophysiology and novel therapeutic strategies. Biomedicines. 2025;13(3):624. https:\/\/doi.org\/10.3390\/biomedicines13030624.","journal-title":"Biomedicines"},{"issue":"4","key":"2340_CR121","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1111\/imj.16603","volume":"55","author":"A Tsatsaronis","year":"2025","unstructured":"Tsatsaronis A, Tiong M, Nicholls K, Ruderman I. Sodium-glucose cotransporter 2 inhibitors reduce albuminuria in patients with Fabry disease: a real\u2010world case series. Intern Med J. 2025;55(4):617\u201321. https:\/\/doi.org\/10.1111\/imj.16603.","journal-title":"Intern Med J"},{"issue":"11","key":"2340_CR122","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12113689","volume":"12","author":"Y Battaglia","year":"2023","unstructured":"Battaglia Y, Bulighin F, Zerbinati L, Vitturi N, Marchi G, Carraro G. Dapaglifozin on albuminuria in chronic kidney disease patients with FabrY disease: the DEFY study design and protocol. Journal of Clinical Medicine. 2023;12(11):3689. https:\/\/doi.org\/10.3390\/jcm12113689.","journal-title":"Journal of Clinical Medicine"},{"issue":"8","key":"2340_CR123","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1093\/eurheartj\/ehac764","volume":"44","author":"I Olivotto","year":"2023","unstructured":"Olivotto I, Udelson JE, Pieroni M, Rapezzi C. Genetic causes of heart failure with preserved ejection fraction: emerging pharmacological treatments. Eur Heart J. 2023;44(8):656\u201367. https:\/\/doi.org\/10.1093\/eurheartj\/ehac764.","journal-title":"Eur Heart J"},{"key":"2340_CR124","doi-asserted-by":"publisher","unstructured":"F. Giallauria et al., New paradigm for the management of cardio-nephro-metabolic syndrome: multidisciplinary approach and role of telemedicine. Minerva Med. 2023;114;3.\u00a0https:\/\/doi.org\/10.23736\/S0026-4806.22.08165-4","DOI":"10.23736\/S0026-4806.22.08165-4"},{"key":"2340_CR125","doi-asserted-by":"publisher","unstructured":"Rangaswami J, Tuttle K, Vaduganathan M. Cardio-Renal-Metabolic care models. Circ Cardiovasc Qual Outcomes. 2020;13(11). https:\/\/doi.org\/10.1161\/CIRCOUTCOMES.120.007264.","DOI":"10.1161\/CIRCOUTCOMES.120.007264"},{"key":"2340_CR126","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2025.1583702","author":"M Iacoviello","year":"2025","unstructured":"Iacoviello M, Gori M, Grandaliano G, Minutolo R, Pitocco D, Trevisan R. A holistic approach to managing cardio-kidney metabolic syndrome: insights and recommendations from the Italian perspective. Front Cardiovasc Med. 2025. https:\/\/doi.org\/10.3389\/fcvm.2025.1583702.","journal-title":"Front Cardiovasc Med"}],"container-title":["Current Cardiology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-025-02340-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11886-025-02340-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-025-02340-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T04:22:18Z","timestamp":1770178938000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11886-025-02340-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,4]]},"references-count":126,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2340"],"URL":"https:\/\/doi.org\/10.1007\/s11886-025-02340-6","relation":{},"ISSN":["1534-3170"],"issn-type":[{"value":"1534-3170","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,4]]},"assertion":[{"value":"3 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"21"}}